Safety and Efficacy of Long-term Somatropin Treatment in Adults

Non-interventional Study of Safety and Efficacy of Long-term Somatropin Treatment in Adults

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01543880

Acronym

NordiWIN

Enrollment

752

Registered

2012-03-05

Start date

2003-07-31

Completion date

2014-06-30

Last updated

2015-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Growth Hormone Deficiency, Growth Hormone Disorder

Brief summary

This study is conducted in Europe. The aim of the study is to evaluate safety and efficacy in adults treated with somatropin (Norditropin®).

Interventions

DRUGsomatropin

Prescribed at the discretion of the treating physician according to product labelling

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* In need of somatropin or current user

Design outcomes

Primary

Measure	Time frame
Number of adverse events	Up to 10 years

Secondary

Measure	Time frame
BMI (Body Mass Index)	Up to 10 years
HbA1c change	Up to 10 years
IGF-I (Insulin-Like Growth Factor I)	Up to 10 years

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026